Ligand profile
C8V
Ligand co-crystallized with this exact protein (Protein Data Bank).
Bound to: KP13_06703 — Carbepenem-hydrolyzing beta-lactamase KPC2
Identifiers
Database identifiers and provenance.
- Ligand ID
C8V- PDB
6b1j- UniProt (this protein)
Q9F663- Target protein
- KP13_06703
Structure
2D representation rendered from SMILES.
Physicochemical properties
Computed with RDKit from SMILES.
Drug-likeness
Descriptor-based ADME screening flags from SMILES. These are not experimental toxicity results.
Estimated from TPSA and LogP only: TPSA ≤ 90 Ų and −1 ≤ LogP ≤ 5 are treated as a favorable small-molecule permeability screen.
- TPSA ≤ 90 Ų 166.2
- −1 ≤ LogP ≤ 5 -2.55
- MW ≤ 500 Da 393.4
- LogP ≤ 5 -2.55
- H-bond donors ≤ 5 5
- H-bond acceptors ≤ 10 8
- Rotatable bonds ≤ 10 6
- TPSA ≤ 140 Ų 166.2
No PAINS structural alerts detected.
Chemical representations
Canonical representations for cheminformatics workflows.
C1C[C@H](CNC1)C(=O)NNC(=O)[C@@H]2CC[C@H](CN2C=O)NOS(=O)(=O)OC1C[C@H](CNC1)C(=O)NNC(=O)[C@@H]2CC[C@H](CN2C=O)NOS(=O)(=O)O
InChI=1S/C13H23N5O7S/c19-8-18-7-10(17-25-26(22,23)24)3-4-11(18)13(21)16-15-12(20)9-2-1-5-14-6-9/h8-11,14,17H,1-7H2,(H,15,20)(H,16,21)(H,22,23,24)/t9-,10-,11+/m1/s1InChI=1S/C13H23N5O7S/c19-8-18-7-10(17-25-26(22,23)24)3-4-11(18)13(21)16-15-12(20)9-2-1-5-14-6-9/h8-11,14,17H,1-7H2,(H,15,20)(H,16,21)(H,22,23,24)/t9-,10-,11+/m1/s1
KMYLRFCWFBWPGR-MXWKQRLJSA-NKMYLRFCWFBWPGR-MXWKQRLJSA-N
Provenance
Annotation context from LigQ_2, the internal Target step that collects PDB, ChEMBL, and ZINC ligand evidence.
- Method
- LigQ sequence
- Source
- PDB
- Binding sites
- PF00144' 'PF13354
External resources
Open this ligand in third-party databases and cheminformatics tools.
- PDB RCSB ligand C8V →
- PDB RCSB structure 6b1j →
- UniProt UniProt Q9F663 (same protein) →
- PubChem PubChem (by InChIKey) →
- Cheminformatics SwissADME prediction →
- Cheminformatics SwissTargetPrediction →
- Web Google Scholar (search “C8V”) →
Other ligands for this protein
Quick navigation to other ligands bound to KP13_06703.
PDB 35
Ligands co-crystallized with this protein (structural evidence).
ChEMBL 100
Compounds with measured inhibitory activity on this target (higher pchembl = more potent).
ZINC 50
Virtual screening candidates selected by structural similarity to known actives (Tanimoto ≥ 0.5).